Signals, Powered By EquityPandit
Lupin has launched Carbidopa tablets in the American market. It used for treating symptoms of Parkinson’s disease and Parkinsonism.
The company stated that, it has launched the product after approval from the United States Food and Drug Administration (USFDA), in the strengths of 25 mg. The product is the generic version of Aton Pharma Inc’s Lodosyn tablets in the same strength.
Furthermore the company added that, the tablets are suggested for use “with Carbidopa-Levodopa or with Levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease, postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.”
